Dr Mehdi Touat
- Spécialité
- Neuro-oncologue, expert tumeurs cérébrales primitives de l'adulte
- Hôpital
- Hôpital Pitié Salpétrière (Paris), APHP, Sorbonne Université, Institut du Cerveau
- Derniers articles
-
- Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study. (1 avr. 2026)
- 18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors. (2 févr. 2026)
- RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma. (8 janv. 2026)
- Dramatic response to entrectinib in a rare glioneuronal tumor harboring an NTRK2 fusion. (27 déc. 2025)
- Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases. (4 août 2025)